OBJECTIVES: To combine clinical results of Endevor® clinical trials and the associated costs of its use in patients with de novo lesions of the coronary arteries. METHODS: An economic model of ENDEAVOR® was constructed based on a retrospective cost-effectiveness analysis. The basic data of the model were taken from the literature and expert opinion, and reflect the clinical and economic consequences of the management of new coronary lesions within the context of the Spanish National Health System. Expert opinion was obtained from semi structured interviews and panel consensus from interventional cardiologists working in seven different Spanish Regions (Autonomias). Only local costs were included, and a discount of 3.5% was applied to the future costs and outcomes. Probabilistic Sensitivity Analysis) PSA, was performed to evaluate robustness of our results. RESULTS: Endeavor® had higher total costs than the bare metal stent and the costs per Target Lesion Revascularization avoided with Endeavor® was €6,851 (per year) and €10,831 (5 years). In terms of costs per Major Adverse Cardiac Event avoided with Endeavor®, the results were €7,003, €8,362 and €11,322, respectively at year 1, 2 and 5 , and the costs per  QALY gained was €132,877, €34,229 and €10,505 at year 1, 2, and 5 years, respectively.The budgetary impact of the progressive introduction of Endeavor® would be practically null, representing 0.4% on the total costs of percutaneous coronary interventions at 5 years. CONCLUSIONS: The use of the Endeavor® stent compared to the Bare metal stent and Coronary artery bypass graft represents an efficient use of resources in coronary artery disease patients, with cost-effectiveness results below the threshold of efficiency defined in Spain. Further real life prospective data related QoL and health care resources utilization may improve model accuracy